View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 21, 2021updated 11 Jul 2022 3:10pm

Takeda reports data from Phase III von Willebrand disease trial

The rVWF prophylaxis decreased spontaneous, treated annualised bleeding rates by 91.5% in prior on-demand treatment patients.

Takeda Pharmaceutical has reported positive data from Phase III clinical trial assessing recombinant von Willebrand factor (rVWF) prophylaxis for von Willebrand disease (VWD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The prospective, open-label, global, multi-centre, 12-month trial had 23 patients with severe VWD, a common inherited bleeding disorder that develops due to VWF deficiency or dysfunction.

It involved the prior on-demand (OD) arm, which recruited subjects who previously took OD VWF, and the switch arm of subjects previously on prophylactic plasma-derived von VWF (pdVWF) therapy, LPB0128.

According to the trial results, rVWF prophylaxis decreased spontaneous, treated annualised bleeding rates (sABRs) in the prior OD arm and the same haemostatic control level was observed in the switch arm, thus meeting the trial’s endpoint.

Compared with historical sABR in prior OD subjects, a 91.5% sABR reduction was seen in those on prophylactic rVWF and the rates were maintained on-study in switch subjects.

The data did not show any new risks or serious adverse events associated with rVWF.

These Phase III trial results are one of the 12 abstracts that Takeda is presenting at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress 2021.

Most of the abstracts analysed the use of prophylaxis in line with the company’s aim to enhance outcomes for rare bleeding disorder patients.

Takeda Pharmaceutical Haematology Global Medical Affairs head Wolfhard Erdlenbruch said: “At Takeda, we are committed to helping make a difference to the lives of patients with rare haematological disorders, both today through our broad portfolio of treatments, and in the future by developing innovative solutions to address unmet needs.

“The data presented at ISTH 2021 highlights the potential for rVWF to address unmet needs in VWD, as well as helping us to understand the clinical and resource utilisation impact when individualising treatment through PK-guided prophylaxis in haemophilia.”

The company also highlighted the Phase III trial of TAK-755, a recombinant ADAMTS13 replacement therapy candidate intended for prophylactic and OD treatment of severe congenital thrombotic thrombocytopenic purpura.

In May 2021, Takeda reported that its vaccine candidate, TAK-003, offered protection against dengue illness and hospitalisation in the Phase III TIDES trial.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena